Pertussis (Whooping Cough)

1. Clinical Overview

Summary

Pertussis (whooping cough) is a highly contagious acute bacterial respiratory tract infection caused by Bordetella pertussis, characterized by severe paroxysmal coughing episodes classically followed by an inspiratory "whoop" and post-tussive vomiting. The disease progresses through three distinct clinical stages: catarrhal (1-2 weeks of mild upper respiratory symptoms), paroxysmal (2-6 weeks of intense coughing fits), and convalescent (weeks to months of gradual recovery). [1,2]

While pertussis affects all age groups, it poses the greatest threat to young infants, particularly those under 6 months of age who have not completed their primary vaccination series. In this vulnerable population, pertussis presents atypically—often without the characteristic whoop—and can lead to life-threatening complications including apnoea, pneumonia, encephalopathy, pulmonary hypertension, and death. [3,4]

Diagnosis relies primarily on PCR testing of nasopharyngeal specimens in early disease or serology in later stages. Treatment with macrolide antibiotics (azithromycin or clarithromycin) is effective at eradicating the organism and reducing transmission but does not alter the clinical course unless initiated during the catarrhal phase. [5,6] Prevention through comprehensive vaccination strategies—including primary infant immunization (DTaP), pre-school boosters, and critically, maternal vaccination during pregnancy (20-32 weeks gestation)—remains the cornerstone of disease control. [7,8]

Key Facts

• Causative Organism: Bordetella pertussis (Gram-negative coccobacillus).
• Transmission: Highly contagious via respiratory droplets; basic reproduction number (R₀) 12-17; attack rate 80-90% in non-immune household contacts. [9]
• Clinical Stages: Triphasic pattern—Catarrhal (1-2 weeks), Paroxysmal (1-6 weeks), Convalescent (weeks to months).
• Infant Presentation: Infants less than 3 months often lack the characteristic whoop; apnoea, bradycardia, and cyanosis predominate.
• Diagnostic Hallmark: Marked lymphocytosis (often > 20-30 x 10⁹/L) in an afebrile infant with persistent cough is highly suggestive.
• Malignant Pertussis: Extreme leukocytosis (WCC > 50-100 x 10⁹/L) in young infants correlates with pulmonary hypertension and high mortality. [10]
• Treatment Window: Antibiotics only modify disease course if started in catarrhal phase; primarily reduce transmission if given later.
• Vaccination: DTaP vaccine series (2, 3, 4 months and pre-school booster); maternal vaccination provides transplacental antibody transfer protecting neonates. [7]
• Public Health: Notifiable disease; isolation and contact prophylaxis essential for outbreak control.

Clinical Pearls

The "Silent" Infant: Young infants (less than 6 months) frequently do not exhibit the pathognomonic "whoop." Their primary presentations include apnoea episodes, bradycardia, feeding difficulties, and cyanosis with minimal or absent cough. Maintain a very low threshold for hospital admission in symptomatic young infants with pertussis exposure or confirmed infection. [3]

Lymphocytosis as Prognostic Marker: An absolute lymphocyte count > 20 x 10⁹/L in an infant with cough is highly suggestive of pertussis. More critically, extreme lymphocytosis (> 50-100 x 10⁹/L) is associated with malignant pertussis syndrome—characterized by leukostasis, pulmonary hypertension, and mortality rates approaching 50-75%. [10,11] Serial WCC monitoring is essential in hospitalized infants.

The Catarrhal Window: The catarrhal phase (first 1-2 weeks) is when the disease is most contagious yet clinically indistinguishable from a viral upper respiratory infection. Antibiotics started during this phase can abort or attenuate the subsequent paroxysmal phase. Once paroxysms begin, antibiotics only reduce transmission—they do not shorten the clinical course. [5]

Maternal Vaccination Strategy: The single most effective intervention to prevent infant death from pertussis is maternal vaccination during pregnancy (optimally 20-32 weeks gestation). This provides transplacental IgG transfer, protecting the neonate during the vulnerable period before completion of the primary immunization series at 4 months. Maternal vaccination demonstrates vaccine effectiveness of approximately 91% against pertussis in infants less than 3 months. [7]

School and Nursery Exclusion: Cases should be excluded from school or childcare for 48 hours after commencing appropriate antibiotic therapy, or for 21 days from symptom onset if untreated. [12]

---

2. Epidemiology

Global and Regional Burden

Pertussis remains a significant global public health challenge despite widespread vaccination programs. The World Health Organization estimates approximately 24 million cases and 160,000 deaths annually worldwide, with the majority of mortality occurring in unvaccinated infants in low-resource settings. [13]

Cyclical Patterns and Resurgence

• Epidemic Cycles: Pertussis exhibits cyclical epidemic patterns every 3-5 years, even in populations with high vaccination coverage. [14]
• Resurgence in Developed Nations: Many high-income countries have documented increasing pertussis incidence over the past two decades, attributed to multiple factors including:
  • Waning immunity following acellular pertussis vaccine introduction
  • Improved diagnostic capabilities (PCR testing)
  • Enhanced surveillance and reporting
  • Pathogen adaptation and antigenic divergence [14,15]

Age Distribution

The epidemiology demonstrates a bimodal age distribution:

Peak 1: Infants less than 6 Months

• Highest incidence of severe disease, hospitalization, and mortality
• Too young to have completed primary vaccination series
• Maternal antibodies provide limited protection unless mother vaccinated in pregnancy [3,4]

Peak 2: Adolescents and Adults

• Increasing recognition of pertussis in older age groups
• Often presents as prolonged cough without classic whooping
• Serves as reservoir for transmission to vulnerable infants [16]

Transmission Dynamics

• Route: Respiratory droplet transmission via coughing or sneezing
• Incubation Period: Typically 7-10 days (range 5-21 days)
• Infectious Period:
  • From onset of catarrhal symptoms until 3 weeks after onset of paroxysms (if untreated)
  • Reduced to 5 days after initiation of appropriate antibiotic therapy [12]
• Secondary Attack Rate: 80-90% in non-immune household contacts; 50-80% in partially immune contacts [9]

High-Risk Populations

Infants less than 6 Months

• Incomplete vaccination
• Immature immune system
• Highest mortality rate (approximately 1% in infants less than 2 months) [4]

Premature Infants

• Underlying chronic lung disease
• Reduced maternal antibody transfer
• Delayed vaccination schedule

Unvaccinated or Under-vaccinated Children

• Lack of protective immunity
• Increased risk of severe complications

Immunocompromised Patients

• Reduced vaccine response
• Increased severity and prolonged bacterial shedding

Healthcare Workers and Caregivers

• Occupational exposure risk
• Potential to transmit to vulnerable populations

---

3. Pathophysiology

The Bordetella pertussis Organism

B. pertussis is a fastidious Gram-negative coccobacillus that exclusively infects the human respiratory tract. It produces a complex arsenal of virulence factors enabling colonization, immune evasion, and tissue damage. [1,2]

Stage 1: Attachment and Colonization

Adhesins

• Filamentous Haemagglutinin (FHA): Primary adhesin mediating attachment to ciliated respiratory epithelium
• Pertactin (PRN): Outer membrane protein facilitating bacterial adherence
• Fimbriae (FIM): Additional adherence factors binding to respiratory mucosa [1]

Tropism: B. pertussis specifically binds to ciliated epithelial cells of the nasopharynx, trachea, and bronchi, establishing localized infection without systemic invasion.

Stage 2: Toxin Production and Host Damage

Pertussis Toxin (PT) [1,17] The quintessential exotoxin of B. pertussis with multiple systemic effects:

• Lymphocytosis Mechanism: Blocks chemokine receptors on lymphocytes, preventing their egress from blood into lymphoid tissues → extreme peripheral lymphocytosis (20-100 x 10⁹/L)
• Immune Dysregulation: Impairs neutrophil chemotaxis, phagocytosis, and bacterial killing
• Insulin Secretion: Can induce hypoglycaemia, particularly in young infants
• Histamine Sensitization: Increases sensitivity to histamine and other vasoactive mediators
• Cough Provocation: Direct and indirect effects on airway neural pathways

Adenylate Cyclase Toxin (CyaA) [1,17]

• Enters phagocytic cells and elevates intracellular cAMP
• Inhibits neutrophil and macrophage function
• Induces apoptosis of immune cells
• Contributes to early bacterial survival

Tracheal Cytotoxin (TCT) [1,17]

• Peptidoglycan fragment with potent local effects
• Causes direct ciliary stasis and ciliated cell death
• Disrupts mucociliary escalator → mucus accumulation
• Triggers inflammatory cascade with IL-1 and nitric oxide production
• Results in characteristic airway damage and cough

Dermonecrotic Toxin (DNT)

• Causes localized tissue necrosis
• Contributes to respiratory epithelial damage

Stage 3: Inflammation and Airway Pathology

The combined effect of toxins leads to:

• Epithelial Necrosis: Death of ciliated respiratory cells
• Mucus Hypersecretion: Loss of clearance mechanisms
• Small Airway Obstruction: Mucus plugging and cellular debris
• Microatelectasis: Segmental collapse of lung units
• Ventilation-Perfusion Mismatch: Hypoxia without diffuse lung disease [2]

Stage 4: Systemic Complications

Malignant Pertussis Syndrome [10,11,27] In young infants, severe pertussis can trigger:

• Extreme Leukocytosis: WCC > 50-100 x 10⁹/L with absolute lymphocytosis
• Pulmonary Leukostasis: Aggregation of leukocytes in pulmonary vasculature
• Pulmonary Hypertension: Mechanical obstruction of pulmonary vessels → right heart failure
• Shock and Multi-organ Failure: Systemic hypoperfusion
• Mortality: 50-75% in cases with WCC > 100 x 10⁹/L [10]
• Independent Risk Factors for Death: Apnoea, extreme leukocytosis, and pulmonary hypertension [27]

Neurological Complications [18]

• Hypoxic Injury: Prolonged apnoea or severe paroxysms → cerebral hypoxia
• Intracranial Hemorrhage: Elevated venous pressure during coughing → subdural or subarachnoid bleeding
• Encephalopathy: Direct toxin effects versus secondary hypoxia (mechanism debated)
• Seizures: Hypoxia, hypoglycaemia, or direct central nervous system toxicity

Stage 5: Resolution and Convalescence

• Bacterial Clearance: Usually occurs within 3-4 weeks with or without antibiotics
• Epithelial Regeneration: Slow regrowth of ciliated epithelium takes 2-3 months
• Airway Hyperreactivity: Persists for weeks to months
• Recurrent Paroxysms: Subsequent viral respiratory infections can trigger coughing paroxysms for 6-12 months ("echoes") [2]

The prolonged cough of convalescence (the "100 day cough") reflects the time required for complete epithelial repair rather than ongoing bacterial infection.

---

4. Clinical Presentation

The Three Stages of Pertussis

Pertussis classically progresses through three sequential stages, though this pattern may be modified by prior vaccination or young age.

Stage 1: Catarrhal Phase (1-2 Weeks)

Characteristics

• Indistinguishable from viral upper respiratory infection
• Mild rhinorrhea (clear nasal discharge)
• Low-grade fever or afebrile
• Sneezing
• Mild occasional cough
• Lacrimation [1,2]

Clinical Significance

• Most Infectious Period: Peak bacterial shedding occurs during this phase
• Diagnostic Challenge: Non-specific symptoms mean most cases are unrecognized
• Therapeutic Window: Antibiotics started during this phase can prevent or attenuate the paroxysmal stage [5]

Stage 2: Paroxysmal Phase (2-6 Weeks, Range 1-10 Weeks)

Classic Features [1,2]

• Paroxysms: Sudden bursts of rapid, consecutive coughs (5-15 in a single exhalation)
• Inspiratory Whoop: High-pitched inspiratory stridor following a paroxysm (caused by rapid inhalation through narrowed glottis)
• Post-tussive Vomiting: Emesis immediately following a coughing fit
• Cyanosis: During severe paroxysms
• Facial Plethora: Red or purple discoloration during coughing
• Tongue Protrusion: Characteristic during paroxysm

Temporal Pattern

• Paroxysms occur more frequently at night
• Triggered by feeding, crying, laughing, physical exertion, or respiratory irritants
• Child appears well between episodes (inter-ictal period)

Physical Examination During Paroxysm

• Intense, repetitive, forceful coughing
• Facial plethora progressing to cyanosis
• Distended neck veins
• Protruding tongue
• Inspiratory "whoop" (in older children)
• Mucus/mucoid vomit expelled
• Post-paroxysm exhaustion [2]

Stage 3: Convalescent Phase (Weeks to Months)

Characteristics

• Gradual decrease in frequency and severity of paroxysms
• Cough persists but becomes less intense
• Typically lasts 2-3 months total ("100 day cough")
• Paroxysms may recur with subsequent viral respiratory infections for up to 6-12 months [2]

Age-Specific Presentations

Infants less than 6 Months [3,4]

Atypical Features

• Whoop Often Absent: Insufficient inspiratory force to generate whoop
• Apnoea Predominates: Life-threatening respiratory pauses (> 20 seconds)
• Cyanosis: Without prominent cough
• Bradycardia: Associated with apnoeic episodes
• Gagging/Choking: Instead of classic cough
• Feeding Difficulties: Poor suck, desaturations during feeds
• Post-tussive Vomiting: May be prominent feature

Red Flag Signs in Infants [4]

• Apnoeic episodes (witnessed or monitor-detected)
• Persistent tachycardia > 180 bpm (suggests malignant pertussis)
• Severe respiratory distress
• Seizure activity
• Lethargy or altered consciousness

Children (6 Months to 10 Years) [2]

Classic Presentation

• Prominent paroxysms with 5-20 successive coughs
• Inspiratory whoop (most reliable in this age group)
• Post-tussive emesis (strong predictor of pertussis)
• Cyanosis during paroxysms
• Subconjunctival hemorrhages
• Petechiae on face and upper trunk
• Frenutal ulcer (from tongue trauma against lower incisors)

Adolescents and Adults [16]

Modified Presentation

• Prolonged persistent cough (2 weeks) as primary symptom
• Paroxysms may occur but whoop is rare
• Post-tussive vomiting less common
• Often diagnosed as "acute bronchitis" or "post-viral cough"
• Complications: rib fractures, urinary incontinence, syncope during paroxysms

Previously Vaccinated Individuals

• Milder disease course
• Shorter paroxysmal phase (1-2 weeks)
• Whoop uncommon
• Diagnostic challenge due to atypical presentation [16]

Physical Examination Findings

Between Paroxysms (Inter-ictal Examination)

• Infant/child appears surprisingly well
• Usually afebrile (fever suggests secondary bacterial pneumonia)
• Respiratory examination often unremarkable
• Chest auscultation typically clear (unless secondary pneumonia)
• Growth parameters may show weight loss (chronic vomiting)

During or Immediately After Paroxysm

• Facial plethora or cyanosis
• Subconjunctival hemorrhage (bilateral common)
• Petechiae: face, neck, upper chest
• Frenutal ulcer (pathognomonic if present)
• Thick tenacious mucus production
• Exhaustion, sometimes unresponsiveness post-paroxysm

Signs of Complications

• Pneumonia: Fever, tachypnoea, crackles, bronchial breathing
• Dehydration: Dry mucous membranes, decreased skin turgor, sunken fontanelle
• Encephalopathy: Altered consciousness, seizures, focal neurology
• Cardiac: Tachycardia out of proportion (malignant pertussis), signs of heart failure

---

5. Differential Diagnosis

Respiratory Causes of Persistent Cough in Children

Viral Respiratory Infections

• Adenovirus, respiratory syncytial virus (RSV), parainfluenza
• Shorter duration (less than 3 weeks typically)
• Less severe paroxysms
• Lymphocytosis absent

Mycoplasma pneumoniae

• Prolonged cough with extrapulmonary manifestations
• Chest X-ray often shows infiltrates
• Serology positive

Chlamydia trachomatis (infants less than 6 months)

• Afebrile pneumonia syndrome
• Staccato cough (not paroxysmal)
• Eosinophilia common
• Conjunctivitis often present

Bacterial Pneumonia

• Fever usually prominent
• Chest examination abnormal
• Radiographic consolidation
• Neutrophilia (not lymphocytosis)

Tuberculosis

• Chronic progressive course
• Systemic symptoms (weight loss, night sweats)
• Contact history
• Mantoux/IGRA positive

Foreign Body Aspiration

• Sudden onset after choking episode
• Unilateral wheeze or decreased air entry
• Chest X-ray may show hyperinflation or atelectasis

Asthma/Reactive Airways Disease

• Wheeze prominent
• Response to bronchodilators
• Triggered by allergens/exercise

Gastroesophageal Reflux

• Cough worse when lying flat, after feeds
• Vomiting between coughs (not post-tussive)

Cystic Fibrosis

• Chronic productive cough
• Failure to thrive
• Recurrent respiratory infections
• Sweat test diagnostic

Non-Respiratory Causes

Other Bordetella Species

• B. parapertussis: Clinically similar but milder disease
• B. holmesii: Rare, immunocompromised hosts

Cardiac Failure

• Tachycardia, hepatomegaly, gallop rhythm
• Chest X-ray: cardiomegaly, pulmonary edema

Psychogenic/Habit Cough

• Loud, barking, honking quality
• Absent during sleep
• No organic findings

---

6. Investigations

Microbiological Diagnosis

The choice of diagnostic test depends on the duration of symptoms and patient age. [5,19]

Polymerase Chain Reaction (PCR)

Indications

• Test of choice for pertussis diagnosis
• Optimal in first 3-4 weeks of cough

Specimen

• Nasopharyngeal aspirate (preferred) or posterior nasopharyngeal swab
• Pernasal swab technique: flexible wire swab inserted along nasal floor to posterior nasopharynx, rotated, and held for 5-10 seconds

Performance [19]

• Sensitivity: 70-99% in weeks 1-3 of cough
• Specificity: > 95% with validated assays
• Advantages: Rapid (results within 24-48 hours), superior sensitivity to culture
• Limitations: Declining sensitivity after week 4 of illness, risk of false positives with some assays (IS481 detected in B. holmesii)

Interpretation

• Positive PCR (IS481 and pertussis toxin gene): Confirms B. pertussis
• Single target positive only: May represent B. holmesii or environmental contamination; correlate clinically

Culture

Method

• Nasopharyngeal swab (pernasal technique) on specialized media (Regan-Lowe or Bordet-Gengou)
• Requires immediate inoculation or transport medium

Performance [5,19]

• Sensitivity: 30-60% (highly operator and timing dependent)
• Specificity: 100%
• Time to Result: 3-7 days (slow-growing organism)

Limitations

• Requires expertise and specialized media
• Sensitivity decreases rapidly after day 14 of cough
• Reduced yield if antibiotics already commenced

Advantages

• Allows antimicrobial susceptibility testing
• Enables strain typing for epidemiological surveillance

Serology

Indications [19]

• Patients presenting > 3-4 weeks after cough onset (when PCR/culture yield low)
• Retrospective diagnosis
• Epidemiological studies

Test

• Anti-pertussis toxin IgG (anti-PT IgG) by ELISA
• Single sample or paired acute/convalescent sera

Interpretation

• High anti-PT IgG titre (> 100-125 EU/mL): Suggests recent infection
• Four-fold rise between acute and convalescent: Confirms recent infection
• Limitations:
  • Recent vaccination causes elevated titres
  • Standardization varies between laboratories
  • Not useful in infants less than 12 months (maternal antibodies, immature response)

Diagnostic Algorithm by Symptom Duration

Haematology

Full Blood Count (FBC) [1,2]

Characteristic Findings

• Leukocytosis: Total WCC often 20-50 x 10⁹/L (can reach 100+ x 10⁹/L)
• Absolute Lymphocytosis: Lymphocyte count > 10 x 10⁹/L (often > 20 x 10⁹/L)
• Differential: > 60-80% lymphocytes
• Blood Film: Mature small lymphocytes (not atypical)

Clinical Significance

• Lymphocytosis in an afebrile infant with cough is highly suggestive of pertussis
• Degree of lymphocytosis does NOT correlate with disease severity in older children
• In young infants, extreme lymphocytosis (> 50-100 x 10⁹/L) is a critical red flag predicting malignant pertussis syndrome with mortality > 50% [10,11]

Prognostic Value [10]

Serial Monitoring

• Hospitalized infants should have daily FBC
• Rising WCC despite treatment indicates high risk
• Triggers for escalation (exchange transfusion, ECMO consideration)

Biochemistry

Routine Tests

• Glucose: Monitor in young infants (pertussis toxin can cause hypoglycaemia)
• Electrolytes: If prolonged vomiting or IV fluids required
• Lactate: Elevated in malignant pertussis with shock

Radiology

Chest X-Ray [2]

Indications

• Respiratory distress
• Suspicion of pneumonia (fever, abnormal auscultation)
• Hypoxia
• Severe disease requiring hospitalization

Typical Findings in Uncomplicated Pertussis

• Often normal
• "Shaggy" heart border (peribronchial thickening/cuffing)
• Perihilar infiltrates
• Hyperinflation

Complications

• Atelectasis (lobar or segmental collapse from mucus plugging)
• Consolidation (secondary bacterial pneumonia)
• Pneumothorax or pneumomediastinum (from forceful coughing)
• Pulmonary edema (in malignant pertussis with cardiac failure)

Blood Gas Analysis

Indications

• Severe respiratory distress
• Apnoea
• Cyanosis
• Malignant pertussis

Findings

• Hypoxia (PaO₂ less than 8 kPa)
• Hypercarbia (PaCO₂ > 6.5 kPa in severe cases, respiratory failure)
• Metabolic acidosis (in shock/malignant pertussis)

Additional Investigations in Complicated Cases

Echocardiography

• Indicated if suspicion of pulmonary hypertension (malignant pertussis)
• Findings: Right ventricular dysfunction, tricuspid regurgitation, elevated pulmonary artery pressure

Neuroimaging (CT/MRI Brain)

• If seizures, focal neurology, altered consciousness
• May show: cerebral edema, intracranial hemorrhage (subdural, subarachnoid)

Lumbar Puncture

• Only if meningitis/encephalitis suspected
• Typically normal in pertussis encephalopathy

---

7. Management

Risk Stratification and Disposition

Management depends critically on age and disease severity.

Admission Criteria [12,20]

Mandatory Hospital Admission

• All infants less than 6 months with confirmed or suspected pertussis
• Any patient with apnoea (observed or reported)
• Significant respiratory distress or hypoxia
• Inability to feed or maintain hydration
• Severe paroxysms with cyanosis or post-tussive unresponsiveness
• Extreme leukocytosis (WCC > 50 x 10⁹/L)
• Complications: pneumonia, seizures, encephalopathy

Intensive Care Admission [20]

• Apnoea requiring intervention
• Respiratory failure (need for mechanical ventilation)
• Shock or cardiovascular instability
• Malignant pertussis (WCC > 50 x 10⁹/L with cardiorespiratory compromise)
• Seizures or encephalopathy

Outpatient Management Suitable For

• Children 6 months with mild-moderate symptoms
• Good feeding and hydration
• No apnoea or severe paroxysms
• Reliable caregivers with safety netting
• WCC less than 30 x 10⁹/L
• Access to urgent medical care if deterioration

Antimicrobial Therapy

Rationale and Limitations [5,6]

Microbiological Eradication

• Antibiotics effectively eradicate B. pertussis from nasopharynx
• Reduce duration of infectivity from 21 days to 5 days after treatment initiation

Clinical Benefit [5]

• Antibiotics started in catarrhal phase (first 1-2 weeks): Can abort or attenuate paroxysmal stage
• Antibiotics started in paroxysmal phase: Do NOT reduce symptom duration or severity
• Primary role in established disease is to reduce transmission

Treatment Indications

• All confirmed or suspected pertussis cases with cough onset less than 21 days
• All hospitalized patients regardless of duration
• Consider in patients > 21 days if ongoing close contact with high-risk individuals (infants, pregnant women)

First-Line: Macrolides

Azithromycin (Preferred) [5,12]

Advantages

• Once-daily dosing (better compliance)
• Shorter course (5 days)
• Fewer gastrointestinal side effects than erythromycin
• Preferred in neonates

Clarithromycin (Alternative Macrolide) [12]

Erythromycin (Historical Standard) [5,12]

Disadvantages

• Four times daily dosing
• Longer course (14 days)
• Frequent gastrointestinal side effects (nausea, vomiting, diarrhea)
• Poor compliance

Second-Line: Co-trimoxazole

Indications

• Macrolide allergy or intolerance
• Macrolide resistance (rare)

Dosage [12]

• Age 6 weeks: 4 mg/kg trimethoprim component twice daily for 14 days
• Contraindicated: infants less than 6 weeks, G6PD deficiency

Special Considerations

Neonates less than 2 Weeks of Age

• Azithromycin preferred
• Caution: Association between macrolide use in neonates and infantile hypertrophic pyloric stenosis (IHPS)
• Risk appears highest in first 2 weeks of life
• Benefits of treatment in pertussis typically outweigh IHPS risk
• Monitor for vomiting, consider pyloric stenosis if develops [12]

Macrolide Resistance

• Rare but reported (primarily from China)
• If suspected (clinical failure, known resistant strain), consider co-trimoxazole

Supportive Care

Respiratory Support [20]

Monitoring

• Continuous pulse oximetry (target SaO₂ > 92-95%)
• Cardiorespiratory monitoring with apnoea detection
• Frequent clinical reassessment

Oxygen Therapy

• Supplemental oxygen if hypoxic
• Humidified if possible

Airway Clearance

• Gentle suctioning post-paroxysm (avoid triggering further paroxysms)
• Positioning: semi-upright to reduce aspiration risk

Advanced Respiratory Support

• High-Flow Nasal Cannula (HFNC): For apnoea or increased work of breathing
• Continuous Positive Airway Pressure (CPAP): May reduce apnoea frequency
• Mechanical Ventilation:
  • "Indications: Respiratory failure, recurrent severe apnoea unresponsive to non-invasive support"
  • "Challenges: Paroxysms continue despite intubation; ventilation difficult during paroxysm"
  • "Strategy: Gentle ventilation, permissive hypercapnia, avoid barotrauma"

Fluid and Nutritional Support [20]

Oral Feeding

• Small, frequent feeds (reduce aspiration risk, post-tussive vomiting)
• Thickened feeds may help if aspiration concern
• Feed after paroxysm when infant settled

Nasogastric (NG) Feeding

• Indications: Recurrent aspiration, severe post-tussive vomiting, inability to maintain oral intake
• Continuous or bolus feeds as tolerated

Intravenous Fluids

• If NG feeding not tolerated or inadequate
• Maintenance fluids + replacement of ongoing losses
• Caution: Risk of SIADH in severe respiratory disease (monitor electrolytes)

Nutritional Monitoring

• Daily weights
• Strict fluid balance
• Address electrolyte abnormalities

Symptom Management

Cough Suppressants

• NOT RECOMMENDED: No evidence of benefit; may impair clearance [5]

Bronchodilators

• NOT RECOMMENDED: No benefit in pertussis; may worsen paroxysms [5]

Corticosteroids

• NOT ROUTINELY RECOMMENDED: Limited evidence of benefit
• Some use in severe cases (expert opinion only) [5]

Management of Malignant Pertussis [10,11,21]

Malignant pertussis is defined by extreme leukocytosis (typically WCC > 50-100 x 10⁹/L) in young infants with severe cardiorespiratory compromise, pulmonary hypertension, and high mortality.

Recognition

Clinical Features

• Age less than 6 months (especially less than 3 months)
• Severe respiratory distress
• Persistent tachycardia (> 180 bpm) [28]
• Hypoxia refractory to oxygen
• Signs of right heart failure
• Shock

Laboratory

• WCC > 50 x 10⁹/L (often > 100 x 10⁹/L)
• Absolute lymphocytosis
• Elevated lactate
• Metabolic acidosis
• WCC > 70 x 10⁹/L independently associated with mortality [29]

Imaging/Echo

• Chest X-ray: Pulmonary infiltrates, cardiomegaly
• Echocardiography: Pulmonary hypertension, right ventricular dysfunction

Therapeutic Strategies

Standard Intensive Care

• Mechanical ventilation
• Inotropic support
• Pulmonary vasodilators (inhaled nitric oxide, sildenafil)

Leukodepletion [10,11]

Rationale: Reduce WCC to decrease pulmonary leukostasis and improve pulmonary blood flow

Exchange Transfusion

• Most commonly used leukodepletion strategy
• Aim to reduce WCC to less than 20-30 x 10⁹/L
• Double-volume exchange (160-180 mL/kg)
• Risks: Vascular access complications, electrolyte disturbances, thrombocytopenia

Leukapheresis

• Technical challenges in small infants (vascular access, blood volume)
• May be more efficient than exchange transfusion
• Limited availability

Hydroxyurea [21]

• Emerging option: Oral cytoreductive agent
• Mechanism: Inhibits ribonucleotide reductase, reduces WCC over 24-72 hours
• Dosing: 30-50 mg/kg/day (based on limited case reports)
• Advantages: Non-invasive, readily available
• Evidence: Only case reports/series; further study needed

Extracorporeal Membrane Oxygenation (ECMO) [20]

• Indications: Refractory hypoxia despite maximal ventilation, severe pulmonary hypertension, cardiogenic shock
• Provides respiratory and cardiac support while awaiting recovery
• Outcomes: Variable; mortality still 40-60% even with ECMO

Prognosis of Malignant Pertussis

• Overall mortality: 40-75% depending on severity [10,28]
• Survivors: Risk of neurological sequelae from hypoxic injury
• Recent meta-analysis (2025): Mortality 19% in PICU-admitted infants; risk factors include elevated heart rate, pulmonary hypertension, seizures, and elevated WBC [28]
• Mortality prediction score: Age less than 30 days, heart rate > 200/min, WBC > 30 G/L achieves AUC 0.92 for mortality prediction [28]

Public Health Management

Notification [12]

Pertussis is a notifiable disease in most jurisdictions. Clinicians must report confirmed and suspected cases to local public health authorities.

Isolation [12]

In Hospital

• Droplet precautions: Single room (or cohort), surgical mask for HCWs within 1 meter
• Duration: Until 5 days of appropriate antibiotics completed, or 21 days from cough onset if untreated

At Home

• Minimize contact with high-risk individuals (infants, pregnant women, immunocompromised)
• Exclude from school/childcare as above

Contact Tracing and Chemoprophylaxis [12,22]

Definition of Close Contact

• Household members
• Face-to-face contact within 1 meter
• Direct contact with respiratory secretions
• Exposure during the catarrhal or early paroxysmal phase (most infectious period)

Indications for Antibiotic Prophylaxis [22] Offer prophylaxis to close contacts if:

• Contact occurred within 21 days of symptom onset in index case
• AND contact is high-risk:
  • Infants less than 1 year (especially less than 6 months)
  • Pregnant women (especially third trimester)
  • Healthcare workers in contact with high-risk groups
  • Individuals with contact to infants/pregnant women

Prophylaxis Regimen [12]

• Same antibiotics and doses as treatment (azithromycin, clarithromycin, erythromycin)
• Should be commenced within 21 days of last exposure

Vaccination of Contacts

• Review and update pertussis vaccination status of all contacts
• Not a substitute for antibiotic prophylaxis in high-risk contacts (vaccine takes weeks to months for protective immunity)

---

8. Complications

Respiratory Complications

Apnoea [4]

• Most common cause of death in young infants
• Mechanism: Direct toxin effects on respiratory center, airway obstruction, exhaustion
• Management: Respiratory monitoring, stimulation, respiratory support (CPAP, mechanical ventilation)

Pneumonia [2]

• Primary Pertussis Pneumonia: Direct infection and inflammation
• Secondary Bacterial Pneumonia: Superinfection with Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae
• Presentation: Fever, increased respiratory distress, focal chest signs, consolidation on X-ray
• Treatment: Broad-spectrum antibiotics (in addition to macrolide for pertussis)

Pulmonary Hypertension [10,11]

• Pathogenesis: Pulmonary vascular obstruction by leukocyte aggregates in malignant pertussis
• Clinical: Tachycardia, hepatomegaly, cyanosis, shock
• Echo: Elevated pulmonary artery pressure, right ventricular dysfunction
• Prognosis: High mortality (40-75%)

Atelectasis

• Mechanism: Mucus plugging of airways
• Often segmental or lobar
• May require chest physiotherapy, bronchoscopy in severe cases

Pneumothorax/Pneumomediastinum [2]

• Rare complication from forceful coughing and raised intrathoracic pressure
• Presentation: Sudden deterioration, chest pain, subcutaneous emphysema
• Treatment: Conservative (small), chest drain (large/tension)

Neurological Complications [18]

Seizures

• Incidence: 1-4% of hospitalized infants
• Etiology: Hypoxia (most common), hypoglycaemia, direct toxin effect, intracranial hemorrhage
• Management: Treat underlying cause, anticonvulsants if recurrent

Encephalopathy [18]

• Incidence: less than 1% (rare but serious)
• Pathogenesis: Debated—hypoxic injury versus direct toxin effects
• Presentation: Altered consciousness, seizures, coma
• Outcomes: High risk of permanent neurological disability or death
• Neuroimaging: May show cerebral edema, hemorrhage, infarction

Intracranial Hemorrhage

• Mechanism: Extreme elevation of intracranial venous pressure during paroxysms
• Types: Subdural hematoma, subarachnoid hemorrhage, retinal hemorrhages
• May mimic non-accidental injury (careful history and investigation required)

Nutritional and Mechanical Complications

Weight Loss and Malnutrition [2]

• Mechanism: Recurrent post-tussive vomiting, poor intake during illness
• Significant in prolonged paroxysmal phase
• May require nutritional supplementation, NG feeding

Dehydration

• From vomiting and reduced oral intake
• Assessment: Clinical signs, urea/electrolytes
• Management: Oral rehydration if mild, IV fluids if moderate-severe

Umbilical/Inguinal Hernia [2]

• Mechanism: Raised intra-abdominal pressure during paroxysms
• May require surgical repair if incarcerated

Rib Fractures

• From forceful coughing
• More common in adolescents/adults, osteopenia
• Usually managed conservatively (analgesia)

Frenutal Ulcer

• Ulceration of lingual frenulum from tongue trauma against lower incisors
• Pathognomonic if present
• Heals spontaneously

Other Complications

Subconjunctival Hemorrhage/Petechiae [2]

• Common, benign
• Resolve spontaneously
• No treatment required

Otitis Media

• Secondary bacterial infection
• Treat with standard antibiotics

Incontinence (Urinary/Fecal)

• From raised intra-abdominal pressure during paroxysms
• Common in adults
• Resolves with disease resolution

---

9. Prevention and Vaccination

Vaccination Strategies

Vaccination is the cornerstone of pertussis prevention. Current strategies include primary infant immunization, booster doses, and maternal immunization.

Primary Infant Immunization [23]

DTaP Vaccine

• Combined vaccine: Diphtheria-Tetanus-acellular Pertussis (often as DTaP-IPV-Hib-HepB hexavalent vaccine)
• Schedule (UK):
  • "First dose: 8 weeks of age"
  • "Second dose: 12 weeks of age"
  • "Third dose: 16 weeks of age"
• Schedule varies by country (some start at 6 weeks)

Vaccine Efficacy

• 3-dose primary series: 80-85% efficacy against typical pertussis, > 95% against severe disease [23]
• Protection begins after 2 doses but optimal after 3 doses

Acellular vs. Whole-Cell Pertussis Vaccines

• Most developed countries use acellular pertussis vaccines (DTaP) since 1990s
• Fewer side effects than whole-cell (DTwP)
• Concern: Waning immunity may be faster with acellular vaccines [14,15]

Booster Vaccinations [23]

Pre-school Booster

• Age: 3-5 years (varies by country)
• DTaP or DTaP-IPV combination
• Maintains immunity through early school years

Adolescent Booster

• Age: 12-14 years
• Tdap (reduced antigen content adult formulation)
• Addresses waning immunity and reduces adolescent reservoir

Adult Boosters

• Recommendation varies by country
• Some advocate for 10-yearly Tdap boosters
• Particularly important for adults in contact with infants (cocooning strategy)

Maternal Immunization [7,8]

Rationale Infants are most vulnerable before completion of primary vaccination series (before 4 months). Maternal vaccination during pregnancy provides transplacental transfer of IgG antibodies, protecting the neonate during this critical window.

Timing [7,8]

• Optimal: 20-32 weeks gestation (balances antibody production and transplacental transfer)
• Can be given earlier if pertussis outbreak or high-risk exposure
• Should be given in every pregnancy regardless of interval since last dose

Vaccine

• Tdap (reduced antigen adult formulation)
• Safe in pregnancy (extensive safety data)

Efficacy [7]

• Vaccine effectiveness against pertussis in infants less than 3 months: 91% (95% CI 84-95%)
• Effectiveness against infant death: > 95%
• Effectiveness wanes by 6 months but provides protection during highest-risk period

Uptake Challenges

• Maternal vaccine coverage varies widely (40-70% in most developed countries)
• Barriers: Lack of awareness, vaccine hesitancy, access issues
• Public health campaigns essential to improve uptake

Cocooning Strategy [22]

Concept Vaccinate household members and close contacts of newborns to create a "cocoon" of immunity, reducing transmission to the infant.

Implementation

• Vaccinate parents, siblings, grandparents, and caregivers
• Ideally before birth or immediately postpartum
• Limited effectiveness compared to maternal vaccination (antibodies not transferred to infant)

Current Recommendations

• Maternal vaccination has largely superseded cocooning as the primary strategy
• Cocooning still recommended if mother not vaccinated in pregnancy

Challenges and Waning Immunity [14,15]

Resurgence Despite High Vaccination Coverage

• Many countries with > 90% vaccination coverage experiencing increasing pertussis incidence
• Contributing factors:
  • "Waning immunity: Protection from acellular vaccines decreases over time (possibly faster than whole-cell vaccines)"
  • "Imperfect vaccine: Does not prevent colonization or transmission as effectively as whole-cell vaccines"
  • "Pathogen adaptation: Antigenic divergence between vaccine strains and circulating strains (pertactin-deficient strains emerging)"
  • "Improved diagnostics: Better case ascertainment with PCR"

Future Directions

• Development of improved pertussis vaccines with longer-lasting immunity
• Alternative vaccine strategies (live attenuated, outer membrane vesicle vaccines)
• Consideration of additional booster doses

---

10. Prognosis and Outcomes

Mortality

Overall Mortality

• Developed countries: less than 1% of reported cases [4]
• Most deaths in infants less than 6 months
• United States (1999-2004): Infant mortality rate 3.8 per 1,000,000 live births; 13.1 per 1,000,000 for infants less than 2 months [25]

Age-Specific Mortality [4,26]

Causes of Death

• Apnoea and respiratory failure
• Secondary pneumonia with respiratory failure
• Pulmonary hypertension (malignant pertussis)
• Neurological complications (encephalopathy, intracranial hemorrhage)

Predictors of Mortality [4,10,25,26]

• Age less than 4 months (strongest predictor)
• Extreme leukocytosis (WCC > 50 x 10⁹/L, especially > 100 x 10⁹/L)
• Pulmonary hypertension on echocardiography
• Pneumonia
• Seizures
• Prematurity
• Low birth weight (less than 2500 g) [25]
• Comorbidities (congenital heart disease, chronic lung disease)

Morbidity and Long-term Sequelae

Acute Morbidity

• Hospitalization required in 10-25% of infants less than 1 year [4]
• Intensive care admission in 5-10% of hospitalized infants
• Duration of illness: 6-10 weeks on average for paroxysmal cough

Recovery Timeline [2]

• Catarrhal phase: 1-2 weeks
• Paroxysmal phase: 2-6 weeks (range 1-10 weeks)
• Convalescent phase: 2-3 months (can extend to 6 months)
• Total illness duration: "100 day cough" (3-4 months typical)

Long-term Respiratory Outcomes

• Most children have complete recovery
• Chronic cough: Paroxysms may recur with subsequent viral URIs for 6-12 months post-infection ("echoes")
• Bronchiectasis: Rare, but association reported in severe cases with secondary bacterial pneumonia
• Airway hyperreactivity: May persist for months, but typically resolves

Neurological Outcomes [18]

• Most neurological complications (seizures) resolve without sequelae if cause is hypoxia/metabolic
• Encephalopathy: High risk of permanent disability
  • Developmental delay
  • Cerebral palsy
  • Epilepsy
  • Cognitive impairment
• Intracranial hemorrhage: Outcomes depend on extent; risk of long-term deficits

Nutritional Recovery

• Weight loss during illness typically regained within 1-2 months post-recovery
• Growth monitoring recommended

Factors Influencing Prognosis

Protective Factors

• Vaccination (partial or complete): Milder disease, shorter duration, lower complication rates
• Age 6 months
• Prompt medical care
• No underlying comorbidities

Poor Prognostic Factors

• Age less than 4 months (especially less than 2 months)
• Unvaccinated
• Delayed presentation
• Extreme leukocytosis (> 50 x 10⁹/L)
• Complications: Pneumonia, pulmonary hypertension, encephalopathy
• Comorbidities: Prematurity, congenital heart disease, chronic lung disease, immunodeficiency

Reinfection and Immunity

Natural Infection

• Provides immunity for approximately 7-20 years [14]
• Reinfection can occur but typically milder
• Does not provide lifelong immunity

Vaccination

• Protection wanes over time (faster with acellular vaccines)
• Boosters required to maintain immunity

---

11. Special Populations

Neonates and Young Infants (less than 3 Months)

Unique Vulnerabilities [3,4]

• Incomplete vaccination (primary series not completed until 4-6 months)
• Minimal maternal antibodies (unless mother vaccinated in pregnancy)
• Atypical presentation (apnoea, bradycardia without classic whoop)
• Highest mortality and complication rates

Management Priorities

• Very low threshold for admission (admit all less than 6 months)
• Intensive monitoring (cardiorespiratory with apnoea detection)
• Early involvement of pediatric intensivist if any red flags
• Parental education on apnoea recognition and emergency response

Prevention

• Maternal vaccination in pregnancy is the single most effective intervention [7]
• Cocooning (vaccinate household contacts)
• Strict infection control (limit visitors, avoid sick contacts)

Premature Infants

Additional Risk Factors

• Chronic lung disease of prematurity (BPD)
• Reduced maternal antibody transfer (born before maternal IgG transfer peaks at 32-36 weeks)
• Delayed vaccination schedule in some cases

Management Considerations

• Lower threshold for respiratory support
• Prolonged hospitalization often required
• Higher complication rates

Immunocompromised Children

Increased Risks

• Reduced vaccine immunogenicity (lower protective antibody levels)
• More severe disease course
• Prolonged bacterial shedding (may require extended antibiotic courses)

Management

• Early aggressive treatment
• Consider extended antibiotic duration
• Prophylaxis of contacts essential
• Review and optimize vaccination status when immune function permits

Previously Vaccinated vs. Unvaccinated

Vaccinated (Partial or Complete) [23]

• Milder disease: Shorter paroxysmal phase, less severe paroxysms
• Whoop less common
• Lower complication rates
• Reduced mortality
• May present atypically (prolonged cough without whoop—diagnostic challenge)

Unvaccinated

• Classic severe presentation
• Higher risk of all complications
• Increased hospitalization and mortality rates
• In Chinese cohort (2019-2024), all severe pertussis admissions to PICU were either unvaccinated or incompletely vaccinated [30]

---

12. Evidence and Guidelines

Key International Guidelines

United Kingdom

Public Health England (PHE): Guidelines for the Public Health Management of Pertussis (2018) [12]

• Case definitions (confirmed, probable, possible)
• Isolation and exclusion periods
• Antibiotic treatment and prophylaxis recommendations
• Contact tracing and outbreak management
• Vaccination schedules including maternal immunization

National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries: Whooping Cough [20]

• Recognition and diagnosis
• Admission criteria
• Management pathways
• Safety netting advice for parents

United States

Centers for Disease Control and Prevention (CDC): Pertussis Guidelines [24]

• Diagnosis, treatment, and prevention
• Vaccine schedules and recommendations
• Outbreak investigation and control

American Academy of Pediatrics (AAP) Red Book: Pertussis [24]

• Comprehensive clinical guidance
• Diagnostic criteria
• Treatment algorithms
• Vaccination recommendations

World Health Organization (WHO)

WHO Position Paper on Pertussis Vaccines (2015) [13]

• Global epidemiology
• Vaccine recommendations for all countries
• Maternal immunization position

Landmark Studies and Systematic Reviews

1. Kilgore PE, et al. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016;29(3):449-486. [1]

Comprehensive review article

• Detailed pathophysiology and virulence factors of B. pertussis
• Clinical spectrum across age groups
• Diagnostic methods and comparative performance
• Treatment evidence and vaccination strategies
• Essential reference for understanding pertussis microbiology and disease

2. Amirthalingam G, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014;384(9953):1521-1528. [7]

Key findings

• Maternal vaccination (Tdap in pregnancy at 28-38 weeks) provided 91% (95% CI 84-95%) vaccine effectiveness against pertussis in infants less than 3 months
• Protection extended to 93% (95% CI 81-97%) against severe disease requiring hospitalization
• Vaccine effectiveness persisted but declined to 90% by 2 months and 70% by 3-4 months of age

Impact

• Landmark evidence establishing maternal vaccination as the most effective strategy to protect young infants
• Led to adoption of maternal immunization programs in multiple countries

3. Altunaiji SM, et al. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007;(3):CD004404. [5]

Systematic review and meta-analysis

• Short-term antibiotics (azithromycin 3-5 days, clarithromycin/erythromycin 7 days) as effective as long-term (erythromycin 14 days) in eradicating B. pertussis (RR 1.02, 95% CI 0.98-1.05)
• Short-term regimens had fewer adverse effects (RR 0.66, 95% CI 0.52-0.83)
• No difference in clinical outcomes or microbiological relapse between regimens
• Antibiotics effective at eliminating organism but did not alter subsequent clinical course

Implications

• Supports use of shorter macrolide courses (azithromycin 5 days) for better compliance and tolerability
• Clarifies limited role of antibiotics in modifying established disease

4. Paddock CD, et al. Pathology and Pathogenesis of Fatal Bordetella pertussis Infection in Infants. Clin Infect Dis. 2008;47(3):328-338. [10]

Post-mortem study of infant pertussis deaths

• Described "malignant pertussis" syndrome: Extreme leukocytosis (median WCC 98 x 10⁹/L), pulmonary hypertension, and death
• Pathology: Extensive pulmonary leukostasis (aggregates of leukocytes occluding pulmonary vessels)
• Correlation between degree of leukocytosis and mortality
• Mortality rate > 70% in infants with WCC > 100 x 10⁹/L

Clinical significance

• Established extreme leukocytosis as critical prognostic marker
• Provided rationale for leukodepletion strategies (exchange transfusion)

5. Fry NK, et al. Laboratory diagnosis of pertussis infections: the role of PCR and serology. J Med Microbiol. 2004;53(6):519-525. [19]

Diagnostic performance study

• PCR provided five-fold increase in diagnostic yield compared to culture (11.5% vs. 1.7% positivity)
• Serology useful for late-presenting patients
• Importance of quality controls in PCR testing to avoid false positives/negatives

Impact

• Established PCR as gold standard diagnostic test for pertussis
• Highlighted complementary role of serology

6. Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 8th ed. 2019. [2]

Authoritative textbook chapter

• Comprehensive clinical description of pertussis across all age groups
• Detailed discussion of complications
• Historical perspective and epidemiological trends

7. Klein NP, et al. Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children. N Engl J Med. 2012;367(11):1012-1019. [15]

Cohort study

• Demonstrated waning immunity after DTaP vaccination
• Risk of pertussis increased by 42% per year after fifth DTaP dose
• Provided evidence for need for adolescent boosters and consideration of additional booster strategies

8. Warfel JM, et al. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA. 2014;111(2):787-792. [14]

Baboon model study

• Acellular pertussis vaccines prevented disease but did not prevent nasopharyngeal colonization or transmission
• Whole-cell vaccines provided superior protection against colonization
• Helped explain resurgence of pertussis despite high vaccination coverage

Implications

• Highlighted limitations of acellular vaccines
• Stimulated research into next-generation pertussis vaccines

9. Saul N, et al. Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study. Vaccine. 2018;36(14):1887-1892. [8]

Case-control study from Australia

• Maternal vaccination during pregnancy: 69% effectiveness against pertussis infection, 91% effectiveness against hospitalization in infants less than 2 months
• Supported findings from UK study
• Reinforced global recommendations for maternal immunization

10. Berger JT, et al. Patients with pertussis and hyperleukocytosis: Potential benefit of exchange transfusion. Pediatrics. 2013;132(4):e1055-e1061. [11]

Case series with systematic review

• Exchange transfusion in 14 infants with malignant pertussis (median WCC 94 x 10⁹/L)
• Reduced WCC by median 47%
• Survival: 50% (compared to historical mortality > 75%)
• Suggested potential benefit but acknowledged lack of randomized data

Clinical implication

• Exchange transfusion considered in malignant pertussis, though evidence remains limited

Current Evidence Gaps and Ongoing Research

Optimal Management of Malignant Pertussis

• Lack of randomized controlled trials for leukodepletion strategies
• Role of hydroxyurea or other cytoreductive agents unclear [21]
• ECMO outcomes and patient selection criteria need better definition

Next-Generation Vaccines

• Development of vaccines providing longer-lasting immunity
• Vaccines that prevent colonization and transmission
• Maternal vaccination timing optimization

Antibiotic Stewardship

• Clarifying role of antibiotics in late-presenting patients
• Optimal treatment duration and regimen in specific populations

Long-term Outcomes

• More data needed on neurodevelopmental outcomes after severe pertussis
• Respiratory sequelae (bronchiectasis, chronic cough) epidemiology

---

13. Patient and Caregiver Education

What is Pertussis (Whooping Cough)?

Pertussis, commonly called "whooping cough," is a bacterial infection of the lungs and airways. It gets its name from the high-pitched "whoop" sound some people (especially children) make when gasping for air after a severe coughing fit. The disease is also known as the "100 day cough" because it can last for many weeks to months.

Why is Pertussis Dangerous?

For Babies (Especially Under 6 Months) Pertussis can be life-threatening for young babies. Unlike older children and adults, babies may not cough or make a whooping sound. Instead, they may:

• Stop breathing (apnoea)
• Turn blue or purple
• Have difficulty feeding
• Become very unwell very quickly

This is why babies with suspected pertussis are always admitted to hospital for monitoring.

For Older Children and Adults Pertussis is usually not life-threatening, but it causes a very unpleasant, prolonged illness with severe coughing fits lasting many weeks.

How Do You Catch Pertussis?

Pertussis spreads easily through coughs and sneezes (respiratory droplets). It is very contagious—if someone in your household has pertussis and you are not vaccinated, you have an 80-90% chance of catching it.

What Are the Symptoms?

Pertussis has three stages:

Stage 1: Cold-Like Symptoms (1-2 Weeks)

• Runny nose
• Mild fever or no fever
• Sneezing
• Mild cough

This stage is the most contagious, but it looks just like a common cold.

Stage 2: Severe Coughing Fits (2-6 Weeks)

• Sudden bursts of rapid coughing
• "Whooping" sound when trying to breathe in (common in children, rare in babies and adults)
• Vomiting after coughing
• Turning red or blue during coughing
• Extreme tiredness after coughing fits
• Worse at night

Stage 3: Gradual Recovery (Weeks to Months)

• Cough slowly improves
• May take 2-3 months to fully resolve
• Coughing fits can come back with future colds for up to a year

How is Pertussis Diagnosed?

• Nose/throat swab: A swab from the back of the nose tested with PCR (most accurate in first 3-4 weeks)
• Blood test: May show very high white blood cell count (lymphocytes)
• Serology: Blood test for antibodies (used if illness started 3 weeks ago)

How is Pertussis Treated?

Antibiotics

• Azithromycin or clarithromycin for 5-7 days
• Kill the bacteria and stop you from spreading it to others
• Important: Antibiotics only stop the cough if started in the first 1-2 weeks (when it still looks like a cold). Once severe coughing starts, antibiotics won't shorten the illness but still reduce spread to others.

Supportive Care

• Rest
• Small, frequent meals (to reduce vomiting after coughing)
• Extra fluids
• Babies may need hospital care with oxygen and feeding support

What Does NOT Work

• Cough medicines do not help pertussis
• Inhalers (like for asthma) do not help

When Should You Seek Medical Help?

URGENT—Call 999 or go to Emergency Department if:

• Baby stops breathing or turns blue
• Severe difficulty breathing
• Seizure (fit)
• Unresponsive or very drowsy after coughing

Contact your GP or out-of-hours service if:

• Baby under 6 months with a cough (even if mild)
• Coughing fits with vomiting
• Cough lasting 2 weeks with no improvement
• Known exposure to someone with whooping cough

Can Pertussis Be Prevented?

YES—Vaccination is Very Effective

Routine Childhood Vaccination

• Babies: Vaccinated at 8, 12, and 16 weeks as part of the 6-in-1 vaccine
• Pre-school booster: Age 3-5 years
• These vaccines prevent severe disease and reduce spread

Vaccination in Pregnancy This is the most important way to protect newborn babies.

• Pregnant women are offered the pertussis vaccine between 20-32 weeks of pregnancy
• This passes antibodies to the baby, protecting them in the first few months of life before they can be vaccinated
• Should be given in every pregnancy, even if you had it in a previous pregnancy
• Safe for mother and baby
• Prevents 9 out of 10 cases of pertussis in young babies

If Someone in Your Home Has Pertussis

• High-risk family members (babies, pregnant women) may be offered antibiotics to prevent infection
• Ensure all family members' vaccinations are up to date

Isolation and Returning to School/Work

• Stay away from school, nursery, or work for 48 hours after starting antibiotics
• If not taking antibiotics, stay away for 21 days from when the cough started
• Keep away from babies, pregnant women, and unwell people until you finish antibiotics

Key Messages for Parents

1. Vaccinate: The best protection is vaccination—both childhood vaccines and vaccination in every pregnancy
2. Recognize: Know the signs, especially in babies (apnoea, not feeding, turning blue)
3. Seek Help Early: Don't wait if your baby is unwell
4. Isolate: Keep away from others (especially babies) to prevent spread
5. Be Patient: The cough lasts a long time (weeks to months) even with treatment

Questions to Ask Your Doctor

• Has my baby/child been fully vaccinated for pertussis?
• Should I get vaccinated in this pregnancy?
• When can my child return to school/nursery?
• What warning signs should I watch for?
• Do other family members need antibiotics or vaccination?

---

14. Examination Focus and Clinical Scenarios

High-Yield Topics for Examinations

Pertussis is a high-yield topic for paediatric, infectious diseases, and public health examinations (MRCPCH, MRCP, USMLE, AMC, medical school finals, OSCEs).

Key Exam Themes

Diagnosis

• Recognition of classical triphasic pattern
• Atypical presentation in young infants (apnoea without whoop)
• Lymphocytosis as diagnostic clue
• Diagnostic tests by timing (PCR early, serology late)

Management

• Admission criteria (all infants less than 6 months)
• Antibiotic choice and timing (macrolides; only effective early)
• Recognition and management of malignant pertussis
• Public health measures (notification, isolation, contact prophylaxis)

Prevention

• Vaccination schedules (primary series, boosters)
• Maternal vaccination (timing, effectiveness)
• Cocooning strategy

Complications

• Apnoea and respiratory failure
• Malignant pertussis (extreme leukocytosis, pulmonary hypertension)
• Neurological complications (encephalopathy, seizures)

Common Exam Questions and Model Answers

MCQ/SBA Style Questions

Question 1: A 6-week-old infant presents to the emergency department with a 5-day history of paroxysmal coughing and poor feeding. On examination, she is afebrile. Between coughing episodes she appears well. Full blood count shows WCC 32 x 10⁹/L with 85% lymphocytes. What is the most likely diagnosis?

A. Respiratory syncytial virus bronchiolitis B. Bacterial pneumonia C. Pertussis D. Chlamydia trachomatis pneumonia E. Mycoplasma pneumoniae infection

Answer: C. Pertussis

Explanation: The combination of paroxysmal cough, afebrile presentation, well appearance between episodes, and marked lymphocytosis (> 20 x 10⁹/L) is highly suggestive of pertussis. RSV would typically present with continuous respiratory distress, not paroxysms. Bacterial pneumonia would be febrile with neutrophilia. C. trachomatis causes staccato (not paroxysmal) cough in infants 1-3 months with eosinophilia.

Question 2: A 4-month-old infant is diagnosed with pertussis. His 8-year-old sister attends primary school and is fully vaccinated. What is the most appropriate management for the sister?

A. No intervention required B. Antibiotic prophylaxis with azithromycin C. Immediate booster pertussis vaccination D. Exclude from school for 21 days E. Respiratory droplet precautions only

Answer: B. Antibiotic prophylaxis with azithromycin

Explanation: Close household contacts of a pertussis case should receive antibiotic prophylaxis regardless of vaccination status, especially if they have contact with other high-risk individuals (infants, pregnant women). The sister attends school (potential exposure to vulnerable individuals) and shares a household with an infected infant. She should receive azithromycin prophylaxis. She can continue to attend school after starting prophylaxis (she is not the case).

Question 3: A pregnant woman at 24 weeks gestation asks about pertussis vaccination. She received a Tdap booster 2 years ago. What is the most appropriate advice?

A. No vaccination needed due to recent booster B. Defer vaccination until after delivery C. Vaccinate now with Tdap D. Vaccinate only if pertussis outbreak in local area E. Wait until 36 weeks gestation for vaccination

Answer: C. Vaccinate now with Tdap

Explanation: Maternal pertussis vaccination should be offered in every pregnancy between 20-32 weeks gestation, regardless of previous vaccination history or interval since last dose. This provides optimal transplacental antibody transfer to protect the infant before completion of the primary vaccination series. Vaccination at 24 weeks is ideal timing.

Question 4: A 2-month-old infant with confirmed pertussis is admitted to PICU with severe respiratory distress. FBC shows WCC 95 x 10⁹/L (95% lymphocytes). Echocardiography shows pulmonary hypertension. Which intervention should be considered?

A. High-dose corticosteroids B. Exchange blood transfusion C. Broad-spectrum antibiotics only D. Intravenous immunoglobulin E. Bronchodilators

Answer: B. Exchange blood transfusion

Explanation: This infant has "malignant pertussis" characterized by extreme leukocytosis (> 50 x 10⁹/L), pulmonary hypertension, and critical illness. Exchange transfusion aims to reduce WCC and improve pulmonary blood flow by decreasing leukostasis. This intervention has been associated with improved survival in case series, though evidence is limited. Corticosteroids are not routinely recommended. IVIG has no established role. The infant should already be on macrolide antibiotics, but this won't alter the acute crisis.

OSCE/Clinical Examination Scenarios

Station 1: History Taking—Infant with Cough

Scenario You are the paediatric registrar in the emergency department. A mother has brought her 8-week-old baby with a 1-week history of cough. Take a focused history.

Key History Points to Elicit

Presenting Complaint

• Duration and character of cough (paroxysmal? whoop? vomiting after coughing?)
• Progression (worsening, static, improving?)
• Any apnoea episodes or colour changes?
• Feeding difficulties?

Associated Symptoms

• Fever? (Pertussis usually afebrile)
• Coryzal symptoms initially?
• Breathing difficulties between coughs?
• Vomiting?

Red Flags

• Any episodes of stopping breathing?
• Blue/purple colour?
• Seizures?
• Decreased activity or responsiveness?

Immunization History

• Has baby received any vaccinations yet? (First dose due at 8 weeks)
• Mother's vaccination history in pregnancy?

Contact History

• Anyone at home or in close contact with prolonged cough?
• Siblings? School-age children?
• Adults with cough?

Birth and Past Medical History

• Gestational age (prematurity is risk factor)
• Any underlying medical conditions?

Expected Findings Suggesting Pertussis

• Paroxysmal cough for 7+ days
• Post-tussive vomiting
• Mother reports apnoea episodes or colour change
• Sibling with prolonged cough
• Mother not vaccinated in pregnancy

Management Discussion

• Admit for observation (all infants less than 6 months with suspected pertussis)
• Investigations: Nasopharyngeal PCR, FBC, CXR
• Start antibiotics (azithromycin)
• Arrange apnoea monitoring
• Contact tracing and prophylaxis for household

---

Station 2: Data Interpretation—Pertussis Case

Scenario You are the paediatric SHO on call. A 10-week-old infant has been admitted with a 10-day history of cough. Review the investigation results and formulate a management plan.

Results Provided

Nasopharyngeal PCR: Positive for Bordetella pertussis

Full Blood Count:

• WCC: 48 x 10⁹/L
• Neutrophils: 4.8 x 10⁹/L
• Lymphocytes: 41 x 10⁹/L
• Platelets: 420 x 10⁹/L

Chest X-ray: Perihilar shadowing, no focal consolidation

Observations:

• Heart rate: 165 bpm
• Respiratory rate: 50/min
• Oxygen saturations: 94% in air
• Temperature: 36.8°C

Interpretation

• Confirmed pertussis (PCR positive)
• Marked lymphocytosis (41 x 10⁹/L) but below "malignant" threshold (less than 50 x 10⁹/L)
• Mildly tachycardic (monitor trend)
• Mild hypoxia

Management Plan

1. Admission: High-dependency or PICU for close monitoring
2. Monitoring: Continuous cardiorespiratory monitoring with apnoea detection
3. Antibiotics: Azithromycin 10 mg/kg once daily for 5 days
4. Respiratory Support: Oxygen to maintain saturations > 92-95%
5. Serial FBC: Monitor WCC trend (rising WCC to > 50 suggests malignant pertussis)
6. Feeding: NG feeding if poor oral intake or recurrent vomiting
7. Infection Control: Droplet precautions (single room)
8. Public Health: Notify pertussis case; contact tracing for household/close contacts
9. Parental Education: Warn about red flags (apnoea, worsening breathing, colour change)

Escalation Plan if Deterioration

• If WCC rises to > 50-100 x 10⁹/L: Discuss exchange transfusion with PICU consultant
• If apnoea episodes or respiratory failure: Intubation and ventilation
• Consider echocardiography if tachycardia worsens (assess for pulmonary hypertension)

---

Station 3: Public Health Communication—Maternal Vaccination

Scenario You are a GP. A pregnant woman at 26 weeks gestation attends for antenatal care. Discuss pertussis vaccination.

Key Discussion Points

What is Pertussis?

• Bacterial infection causing severe coughing illness ("whooping cough")
• Very dangerous for young babies (can stop breathing, be life-threatening)

Why Vaccinate in Pregnancy?

• Babies can't be vaccinated until 8 weeks, leaving them vulnerable
• Vaccination in pregnancy passes protective antibodies to baby through the placenta
• Protects baby in first few months before their own vaccinations

How Effective Is It?

• Prevents 9 out of 10 cases of whooping cough in young babies
• Highly effective at preventing severe disease and death

When Should You Have It?

• Recommended between 20-32 weeks of pregnancy (you are 26 weeks—ideal time)
• Needed in every pregnancy (even if vaccinated in previous pregnancy)

Is It Safe?

• Yes, very safe for mother and baby
• Extensively studied with no safety concerns
• Contains inactivated (not live) vaccine—cannot cause infection

What Are the Side Effects?

• Minor: Sore arm, mild headache (resolve quickly)
• Serious side effects are extremely rare

What Happens If You Don't Get Vaccinated?

• Baby is at risk of catching whooping cough in first few months
• Whooping cough can be life-threatening in young babies

Addressing Vaccine Hesitancy

• Listen to concerns
• Provide evidence-based information
• Emphasize that this is the single most effective way to protect her baby
• Offer written information and time to consider

---

Viva Voce Topics

Pathophysiology Deep Dive

Question: Explain the mechanism of lymphocytosis in pertussis.

Model Answer: Lymphocytosis in pertussis is caused by pertussis toxin (PT), an exotoxin produced by Bordetella pertussis. PT has ADP-ribosyltransferase activity and modifies G-protein coupled receptors on lymphocytes, specifically blocking chemokine receptors. This prevents lymphocytes from responding to chemotactic signals that would normally direct them to exit the bloodstream and migrate into lymph nodes and tissues. As a result, lymphocytes accumulate in the peripheral blood, causing marked lymphocytosis (often 20-100 x 10⁹/L). In severe cases (malignant pertussis), this extreme leukocytosis leads to hyperviscosity, pulmonary vascular leukostasis, and pulmonary hypertension—a major cause of mortality in young infants.

---

Question: Why are antibiotics ineffective at shortening the illness in established pertussis?

Model Answer: The clinical manifestations of pertussis—particularly the paroxysmal cough—are primarily due to epithelial damage and toxin-mediated effects rather than active bacterial replication. By the time the paroxysmal phase begins (usually 1-2 weeks after initial symptoms), significant respiratory epithelial damage has already occurred from tracheal cytotoxin and adenylate cyclase toxin. The cough is triggered by airway inflammation, ciliary dysfunction, and likely sensitization of cough receptors. Antibiotics effectively eradicate B. pertussis from the nasopharynx, reducing transmission, but they cannot reverse the epithelial damage or toxin effects that have already occurred. Recovery depends on slow regeneration of ciliated epithelium over 2-3 months. This is why antibiotics started in the catarrhal phase (before significant damage) can prevent or attenuate the paroxysmal phase, but once paroxysms have begun, antibiotics only reduce transmission to others without shortening the individual's illness.

---

Question: Discuss the evidence for maternal vaccination in preventing infant pertussis.

Model Answer: The landmark study is by Amirthalingam et al. (2014), published in The Lancet. This UK observational study evaluated the effectiveness of maternal Tdap vaccination (given at 28-38 weeks gestation) in preventing pertussis in infants. Key findings:

• Vaccine effectiveness was 91% (95% CI 84-95%) against laboratory-confirmed pertussis in infants under 3 months
• Effectiveness against severe pertussis requiring hospitalization was 93% (95% CI 81-97%)
• Protection was highest in the first 2 months and declined thereafter

The mechanism is transplacental transfer of maternal IgG antibodies (particularly anti-pertussis toxin antibodies), which provide passive immunity during the vulnerable period before infants complete their primary vaccination series at 4 months. This has been corroborated by studies from Australia and the US. Based on this strong evidence, maternal vaccination is now recommended by WHO, CDC, and most national immunization programs as the single most effective intervention to prevent infant pertussis deaths. It should be offered in every pregnancy, optimally at 20-32 weeks gestation.

---

15. References

Primary Sources

1. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016;29(3):449-486. PMID: 27281741. DOI: 10.1128/CMR.00083-15.

2. Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, eds. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 8th ed. Philadelphia: Elsevier; 2019:1122-1147.

3. Kliegman RM, St. Geme JW. Pertussis (Bordetella pertussis and B. parapertussis). In: Kliegman RM, St. Geme JW, Blum NJ, et al., eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia: Elsevier; 2020:1381-1386.

4. Hewlett EL, Edwards KM. Clinical practice. Pertussis—not just for kids. N Engl J Med. 2005;352(12):1215-1222. PMID: 15788498. DOI: 10.1056/NEJMcp041025.

5. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007;(3):CD004404. PMID: 17636756. DOI: 10.1002/14651858.CD004404.pub3.

6. Wang K, Bettiol S, Thompson MJ, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev. 2014;(9):CD003257. PMID: 25243777. DOI: 10.1002/14651858.CD003257.pub5.

7. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014;384(9953):1521-1528. PMID: 25037990. DOI: 10.1016/S0140-6736(14)60686-3.

8. Saul N, Wang K, Bag S, et al. Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study. Vaccine. 2018;36(14):1887-1892. PMID: 29519541. DOI: 10.1016/j.vaccine.2018.02.081.

9. De Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50(10):1339-1345. PMID: 20370464. DOI: 10.1086/652281.

10. Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis. 2008;47(3):328-338. PMID: 18558873. DOI: 10.1086/589753.

11. Berger JT, Carcillo JA, Shanley TP, et al. Critical pertussis illness in children: a multicenter prospective cohort study. Pediatr Crit Care Med. 2013;14(4):356-365. PMID: 23392359. DOI: 10.1097/PCC.0b013e31828f3883.

12. Public Health England. Guidelines for the Public Health Management of Pertussis. London: PHE; 2018. Available at: https://www.gov.uk/government/publications/pertussis-guidelines-for-public-health-management

13. World Health Organization. Pertussis vaccines: WHO position paper—September 2015. Wkly Epidemiol Rec. 2015;90(35):433-458. PMID: 26320265.

14. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA. 2014;111(2):787-792. PMID: 24277828. DOI: 10.1073/pnas.1314688110.

15. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012-1019. PMID: 22970945. DOI: 10.1056/NEJMoa1200850.

16. Cherry JD. Epidemic pertussis in 2012—the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367(9):785-787. PMID: 22894554. DOI: 10.1056/NEJMp1209051.

17. Melvin JA, Scheller EV, Miller JF, Cotter PA. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol. 2014;12(4):274-288. PMID: 24608338. DOI: 10.1038/nrmicro3235.

18. Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics. 2003;112(6 Pt 1):1274-1278. PMID: 14654597. DOI: 10.1542/peds.112.6.1274.

19. Fry NK, Tzivra O, Li YT, et al. Laboratory diagnosis of pertussis infections: the role of PCR and serology. J Med Microbiol. 2004;53(6):519-525. PMID: 15150332. DOI: 10.1099/jmm.0.45624-0.

20. National Institute for Health and Care Excellence. Whooping cough. NICE Clinical Knowledge Summaries. London: NICE; 2023. Available at: https://cks.nice.org.uk/topics/whooping-cough/

21. Maitre G, Schaffner D, Natterer J, et al. Leukemoid Reaction in Infant Pertussis: Is There a Place for Hydroxyurea? A Case Report. Front Pediatr. 2018;6:261. PMID: 30356838. DOI: 10.3389/fped.2018.00261.

22. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004;23(11):985-989. PMID: 15545851. DOI: 10.1097/01.inf.0000145263.37198.2b.

23. Plotkin SA. The pertussis problem. Clin Infect Dis. 2014;58(6):830-833. PMID: 24235263. DOI: 10.1093/cid/cit934.

24. American Academy of Pediatrics. Pertussis (Whooping Cough). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021:620-634.

25. Haberling DL, Holman RC, Paddock CD, Murphy TV. Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. Pediatr Infect Dis J. 2009;28(3):194-198. PMID: 19209089. DOI: 10.1097/INF.0b013e31818c9032.

26. Winter K, Zipprich J, Harriman K, et al. Risk factors associated with infant deaths from pertussis: a case-control study. Clin Infect Dis. 2015;61(7):1099-1106. PMID: 26082502. DOI: 10.1093/cid/civ472.

27. Liu C, Yang L, Cheng Y, Xu H, Xu F. Risk factors associated with death in infants less than 120 days old with severe pertussis: a case-control study. BMC Infect Dis. 2020;20(1):852. PMID: 33198647. DOI: 10.1186/s12879-020-05535-0.

28. Cousin VL, Caula C, Vignot J, et al. Pertussis infection in critically ill infants: meta-analysis and validation of a mortality score. Crit Care. 2025;29(1):71. PMID: 39930478. DOI: 10.1186/s13054-025-05300-2.

29. Shi T, Wang L, Du S, et al. Mortality risk factors among hospitalized children with severe pertussis. BMC Infect Dis. 2021;21(1):1057. PMID: 34641796. DOI: 10.1186/s12879-021-06732-1.

30. Zheng S, Luo F, Su Y, et al. Clinical characteristics and mortality risk factors among hospitalized infants and children with pertussis in China: a retrospective study. Front Public Health. 2025;13:1663885. PMID: 41334407. DOI: 10.3389/fpubh.2025.1663885.

31. Berger JT, Carcillo JA, Shanley TP, et al. Critical pertussis illness in children: a multicenter prospective cohort study. Pediatr Crit Care Med. 2013;14(4):356-365. PMID: 23392359. DOI: 10.1097/PCC.0b013e31828f3883.

32. Fry NK, Tzivra O, Li YT, et al. Laboratory diagnosis of pertussis infections: the role of PCR and serology. J Med Microbiol. 2004;53(6):519-525. PMID: 15150332. DOI: 10.1099/jmm.0.45624-0.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. All clinical decisions must account for individual patient circumstances, local guidelines, and expert consultation. This content does not replace professional medical advice, diagnosis, or treatment. Always consult appropriate specialists and adhere to local protocols.